Amity Institute of Public Health, Amity University, Noida, UP, India
Research Article
A Prospective, Multicentre, Single Arm Clinical Study to Evaluate the Effect of Saroglitazar on Non High-Density Lipoprotein Cholesterol in Patients with Diabetic Dyslipidemia Inadequately Controlled with Diet, Exercise, and Statin-The GLIDDER Study
Author(s): Upendra Kaul*, Priyadarshini Arambam, Ranjan Kachru, Vineet Bhatia, Yumnam Diana, Nungshijungla, Mitesh Shah, Krupi Parmar, Ashok Jaiswal and Peeyush Jain
Objective: Diabetic dyslipidemia is highly atherogenic as it is associated with high triglyceride (TG), high small dense low-density lipoprotein (sd-LDL) particles and low high-density lipoprotein cholesterol (HDL-C). Saroglitazar, a dual peroxisome proliferator activated receptor agonist (predominant PPAR-α agonist and modest PPAR-γ agonist), is approved in India for the management of diabetic dyslipidemia. The GLIDDER study was done to evaluate the effects of Saroglitazar 4 mg on non HDL-C as the primary endpoint and sd-LDL particles as a secondary endpoint in diabetic patients with dyslipidemia.
Methods: This study was a 24 weeks, prospective, multicentre, single arm study conducted in 104 patients with diabetic dyslipidemia (TG ≥ 200 mg/dL) inadequately controlled w.. Read More»
DOI:
10.35248/2155-6156.19.10.819
